RECRUITING

APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO)

Talk to us

Conditions

Kidney DiseasesKidney FailureKidney Disease, ChronicApolopoprotein L1 gene (APOL1)Kidney TransplantationKidney DonorUnited Network for Organ Sharing (UNOS)Association of Organ Procurement Organizations (AOPO)Kidney Transplantation Outcomes Network

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The APOLLO study is being done in an attempt to improve outcomes after kidney transplantation and to improve the safety of living kidney donation based upon variation in the apolipoprotein L1 gene (APOL1). Genes control what is inherited from a family, such as eye color or blood type. Variation in APOL1 can cause kidney disease. African Americans, Afro-Caribbeans, Hispanic Blacks, and Africans are more likely to have the APOL1 gene variants that cause kidney disease. APOLLO will test DNA from kidney donors and recipients of kidney transplants for APOL1 to determine effects on kidney transplant-related outcomes.

Official Title

APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO)

Quick Facts

Study Start:2019-03-21
Study Completion:2025-12-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT03615235

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:Not specified
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:CHILD, ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. Age 18 years or older
  2. Willing and able to provide informed consent
  3. Able to understand and follow study procedures
  4. Stable medical condition
  1. Pregnancy or breastfeeding
  2. Severe psychiatric disorders
  3. Active substance abuse
  4. Unstable medical conditions
  5. Inability to comply with study requirements

Contacts and Locations

Study Contact

Laurie P. Russell, MS
CONTACT
336-713-4292
lrussell@wakehealth.edu
Benjamin Bagwell, BS
CONTACT
336-716-5777
bbagwell@wakehealth.edu

Principal Investigator

Barry I. Freedman, MD
PRINCIPAL_INVESTIGATOR
Wake Forest University Health Sciences
David M. Reboussin, PhD
PRINCIPAL_INVESTIGATOR
Wake Forest University Health Sciences
Paul L. Kimmel, MD
STUDY_DIRECTOR
Natl Institute of Diabetes, Digestive & Kidney Diseases
Marva Moxey-Mims, MD
STUDY_CHAIR
Children's Natl Health System; George Washington Univ Sch of Med and Health Serv

Study Locations (Sites)

University of Alabama at Birmingham
Birmingham, Alabama, 35233
United States
University of California San Francisco
San Francisco, California, 94143
United States
University of Miami / Miami Transplant Institute
Miami, Florida, 33133
United States
Emory University School of Medicine
Atlanta, Georgia, 30322
United States
University of Maryland School of Medicine
Baltimore, Maryland, 21201
United States
Johns Hopkins University
Baltimore, Maryland, 21205
United States
Joslin Diabetes Center / Harvard University
Boston, Massachusetts, 02215
United States
University of Michigan Medicine
Ann Arbor, Michigan, 48109
United States
Saint Louis University Center for Transplantation
Saint Louis, Missouri, 63104
United States
Ichan School of Medicine at Mount Sinai
New York, New York, 10029
United States
Columbia University Irving Medical Center
New York, New York, 10032
United States
Weill Cornell Medicine
New York, New York, 10065
United States
Duke University
Durham, North Carolina, 27705
United States
Wake Forest School of Medicine
Winston-Salem, North Carolina, 27157
United States
Cleveland Clinic
Cleveland, Ohio, 44106
United States
University of Pennsylvania
Philadelphia, Pennsylvania, 19104
United States
Vanderbilt University Medical Center
Nashville, Tennessee, 37232
United States
University of Wisconsin - Madison
Madison, Wisconsin, 53792
United States

Collaborators and Investigators

Sponsor: Wake Forest University Health Sciences

  • Barry I. Freedman, MD, PRINCIPAL_INVESTIGATOR, Wake Forest University Health Sciences
  • David M. Reboussin, PhD, PRINCIPAL_INVESTIGATOR, Wake Forest University Health Sciences
  • Paul L. Kimmel, MD, STUDY_DIRECTOR, Natl Institute of Diabetes, Digestive & Kidney Diseases
  • Marva Moxey-Mims, MD, STUDY_CHAIR, Children's Natl Health System; George Washington Univ Sch of Med and Health Serv

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2019-03-21
Study Completion Date2025-12-31

Study Record Updates

Study Start Date2019-03-21
Study Completion Date2025-12-31

Terms related to this study

Keywords Provided by Researchers

  • Apolopoprotein L1 gene (APOL1)
  • Kidney Transplantation
  • Kidney Donor
  • United Network for Organ Sharing (UNOS)
  • Association of Organ Procurement Organizations (AOPO)
  • Kidney Transplantation Outcomes Network

Additional Relevant MeSH Terms

  • Kidney Diseases
  • Kidney Failure
  • Kidney Disease, Chronic